Methylphenidate in Progressive Supranuclear Palsy [PSP] – Old drug, New Indications?
Objective: To evaluate whether Methylphenidate can improve some symptoms of PSP. Background: PSP is a neurodegenerative disorder with limited therapeutic options. Methylphenidate[MPH] , a drug…Vascular parkinsonism: Clinical features and comparison with Parkinson’s disease
Objective: To define the clinical features of vascular parkinsonism (VP) and compare it to idiopathic Parkinson’s disease (iPD). Background: The main differential diagnosis of VP…The Timed Up & Go test (time) is inversely associated with fall frequency in progressive supranuclear palsy
Objective: This study aimed to elucidate the appropriate assessments associated with fall frequency in progressive supranuclear palsy (PSP). Background: PSP is an adult-onset neurodegenerative disease,…Atypical Response to Apomorphine in a Patient with Multiple System Atrophy
Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…Effects of mannitol treatment in a mice model of multiple system atrophy (MSA)
Objective: The aim of this study was to examine the effect of mannitol treatment in a mice model of MSA. Background: Alpha-synuclein aggregation represents the…Midbrain/pons area ratio and clinical features predict the prognosis of PSP
Objective: This study aims to characterize the natural history of PSP and to find predictors of shorter survival and early institutionalization including neuroimaging biomarkers. Background:…Analysis of Tau Burden and Distribution on the Spectrum of PSP Subtypes
Objective: The aim of this study was to assess the previous hypothesis about relationship between clinical spectrum of Progressive Supranuclear Palsy (PSP) and tau burden…Amyotrophic Lateral Sclerosis-Progressive Supranuclear Palsy Phenotype with Negative C9ORF72 Mutation
Objective: We report a rare case of amyotrophic lateral sclerosis (ALS) / progressive supranuclear palsy (PSP) phenotype. Background: Increasing evidence supports a common pathophysiology between…Evolution of diagnostic certainty and PSP-predominance types in 187 pathologically confirmed PSP patients
Objective: To examine the evolution of diagnostic certainty and clinical predominance types as defined by the movement disorder society (MDS) criteria for the clinical diagnosis…Referral and diagnostic time intervals from symptom onset to death in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Parkinson’s disease (PD)
Objective: To compare referral and diagnostic time intervals from index symptom to death in PSP/CBD and age-sex matched PD. Background: Misdiagnosis and delayed diagnosis are…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.